These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2996299)

  • 1. Neuropeptide Y is a potent inhibitor of cyclic AMP accumulation in feline cerebral blood vessels.
    Fredholm BB; Jansen I; Edvinsson L
    Acta Physiol Scand; 1985 Jul; 124(3):467-9. PubMed ID: 2996299
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuropeptide Y: immunocytochemical localization to and effect upon feline pial arteries and veins in vitro and in situ.
    Edvinsson L; Emson P; McCulloch J; Tatemoto K; Uddman R
    Acta Physiol Scand; 1984 Oct; 122(2):155-63. PubMed ID: 6549101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the contractile effect of neuropeptide Y in feline cerebral arteries.
    Edvinsson L
    Acta Physiol Scand; 1985 Sep; 125(1):33-41. PubMed ID: 2864784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of calcitonin gene-related peptide receptors in human cerebral vessels. Vasomotor responses and cAMP accumulation.
    Jansen I; Mortensen A; Edvinsson L
    Ann N Y Acad Sci; 1992 Jun; 657():435-40. PubMed ID: 1322097
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanisms underlying pre- and postjunctional effects of neuropeptide Y in sympathetic vascular control.
    Pernow J; Saria A; Lundberg JM
    Acta Physiol Scand; 1986 Feb; 126(2):239-49. PubMed ID: 3010640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
    Rose RJ; Liu H; Palmer D; Maurice DH
    Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-related decrease in beta adrenergic receptor-mediated vascular smooth muscle relaxation.
    Tsujimoto G; Lee CH; Hoffman BB
    J Pharmacol Exp Ther; 1986 Nov; 239(2):411-5. PubMed ID: 2430092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
    Birk S; Edvinsson L; Olesen J; Kruuse C
    Eur J Pharmacol; 2004 Apr; 489(1-2):93-100. PubMed ID: 15063160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cilostazol, a phosphodiesterase type III inhibitor, on histamine-induced increase in [Ca2+]i and force in middle cerebral artery of the rabbit.
    Shiraishi Y; Kanmura Y; Itoh T
    Br J Pharmacol; 1998 Mar; 123(5):869-78. PubMed ID: 9535015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A low dose of forskolin increases cyclic AMP levels and cyclic AMP dependent protein kinase activity in bovine coronary arteries without causing relaxation.
    Vegesna RV; Diamond J
    Proc West Pharmacol Soc; 1984; 27():189-92. PubMed ID: 6093128
    [No Abstract]   [Full Text] [Related]  

  • 11. Phorbol ester modulation of cyclic AMP accumulation in a primary culture of rat aortic smooth muscle cells.
    Phaneuf S; Berta P; Peuch LP; Haiech J; Cavadore JC
    J Pharmacol Exp Ther; 1988 Jun; 245(3):1042-7. PubMed ID: 2838600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre- and postjunctional effects of NPY on sympathetic control of rat femoral artery.
    Lundberg JM; Pernow J; Tatemoto K; Dahlöf C
    Acta Physiol Scand; 1985 Apr; 123(4):511-3. PubMed ID: 3838851
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacological properties of prejunctional alpha-adrenoceptors in isolated feline middle cerebral arteries; comparison with the postjunctional alpha-adrenoceptors.
    Skärby T
    Acta Physiol Scand; 1984 Oct; 122(2):165-74. PubMed ID: 6151335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function.
    Lundberg JM; Terenius L; Hökfelt T; Martling CR; Tatemoto K; Mutt V; Polak J; Bloom S; Goldstein M
    Acta Physiol Scand; 1982 Dec; 116(4):477-80. PubMed ID: 6763452
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuropeptide Y induces potent contraction of arterial vascular smooth muscle via an endothelium-independent mechanism.
    Pernow J; Lundberg JM
    Acta Physiol Scand; 1988 Sep; 134(1):157-8. PubMed ID: 3239419
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of neuropeptide Y on contraction, relaxation, and membrane potential of rabbit cerebral arteries.
    Abel PW; Han C
    J Cardiovasc Pharmacol; 1989 Jan; 13(1):52-63. PubMed ID: 2468936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system.
    Pons J; Kitlinska J; Ji H; Lee EW; Zukowska Z
    Can J Physiol Pharmacol; 2003 Feb; 81(2):177-85. PubMed ID: 12710532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of acute hypoxia on some second messengers in pulmonary and cerebral arterial endothelial and smooth muscle cells].
    Hu Q; Wang D
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Feb; 20(1):17-22. PubMed ID: 11367728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of phosphodiesterase inhibitors on cyclic nucleotide levels and relaxation of pig coronary arteries.
    Kramer GL; Wells JN
    Mol Pharmacol; 1979 Nov; 16(3):813-22. PubMed ID: 231194
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of colforsin, trequinsin and isoprenaline on norepinephrine-induced contractions and cyclic nucleotide levels of isolated vascular tissue.
    Linz W; Wiemer G; Schölkens BA
    Arzneimittelforschung; 1988 Feb; 38(2):240-3. PubMed ID: 2835960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.